Report generated with Calculate by QxMD at https://www.qxmd.com/calculate
Over 400 decision support tools available • get the app for iOS or Android at qx.md/calculate
The original International Prognostic Index (IPI) was developed and validated prior to the addition of rituximab to curative anthracycline-based chemotherapy.
Clinical trials have confirmed that rituximab improves the survival of individuals with diffuse large B-cell lymphoma. Using a database of patients treated in the rituximab era (the National Comprehensive Cancer Network database consisting of 1935 patients), this enhanced IPI score is able to discriminate individuals based on 5 clinical predictors (and an 8 point scoring system).
The final score is able to differentiate patients into four distinct prognostic groups for overall survival (low, low-intermediate, high-intermediate, and high risk).
The original IPI was developed by Shipp et al.
The enhanced NCCN-IPI offers improved discrimination for the overall survival of low- and high-risk patients in the rituximab era.
References
Shipp et al. The International Non-Hodgkinâs Lymphoma Prognostic Factors Project.
A predictive model for aggressive non-Hodgkinâs lymphoma.
N Engl J Med 1993;32:987-994.
Zhou et al.
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era.
Blood 2014;123:837-42.
Do you have an enquiry or suggestion? Get in touch with us through Twitter @QxMD, Facebook QxMD, or email [email protected]